

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Nanjing Leads Biolabs Co., Ltd.
南京维立志博生物科技股份有限公司

(A joint stock company established in the People's Republic of China with limited liability)

(Stock Code: 9887)

VOLUNTARY ANNOUNCEMENT

**PROPOSED ON-MARKET ACQUISITION OF H SHARES BY
THE TRUSTEE IN
THE AMOUNT OF UP TO US\$50 MILLION UNDER
THE H SHARE AWARD SCHEME**

This announcement is made by Nanjing Leads Biolabs Co., Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis.

The Company wishes to announce that it has instructed the Trustee to acquire additional H Shares through on-market transactions at the prevailing market price (“**Share Purchase**”), utilizing Scheme Funds in an aggregate amount of up to US\$50 million, in accordance with the H Share Award Scheme Rules. The Trustee has previously acquired certain H Shares in 2025 in accordance with the instructions of the Company under the H Share Award Scheme Rules. The abovementioned Target Shares purchased will serve as the source of Awarded Shares to be granted to the Grantees upon the fulfillment of the relevant vesting conditions under the H Share Award Scheme. Unless otherwise defined, capitalized terms used in this announcement shall have the same meanings as those defined in the H Share Award Scheme Rules and the Circular (as defined below).

Reference is made to the circular of the Company dated November 28, 2025 (the “**Circular**”) and the poll results announcement of the Company dated December 17, 2025 in relation to, among other things, the approval by the Shareholders at the EGM of the adoption of the H Share Award Scheme. According to the H Share Award Scheme Rules, the Trustee will acquire existing H Shares as Target Shares through on-market transactions on the secondary market at the prevailing market price by utilizing the Scheme Funds in accordance with the instructions of the Company and the relevant provisions of the H Share Award Scheme Rules, and such Target Shares will be held by the Trustee and used to satisfy the Awarded Shares to be granted to the Eligible Participants under the H Share Award Scheme.

The board of directors (the “**Board**”) of the Company believes that maintaining a reserve of Shares acquired at competitive prices will enhance the Group’s flexibility in structuring effective compensation and remuneration packages, thereby strengthening its ability to attract and retain talents necessary for the Group’s continued growth and development. The Share Purchase shall be made based on the needs of the Company and with reference to prevailing market conditions. Any Target Shares purchased by the Trustee will be held by it for the purposes set out in the trust deed entered into between the Company and the Trustee constituting the H Share Award Scheme and in accordance with the Scheme Rules. The Trustee shall not exercise any voting rights attached to any Target Shares held by the Trustee under the H Share Award Scheme. The payment of the contributed amounts, if any, will be funded by the own financial resources of the Company, and will not impact the Company’s operations.

The Board believes that the Share Purchase demonstrates the Company’s confidence in its business outlook and prospects and will, in the long term, benefit the Company and enhance value for its Shareholders. The Board further believes that the Company has sufficient financial resources to implement the Share Purchase while maintaining a solid financial position.

Shareholders and potential investors should note that any Share Purchase will be subject to market conditions and other factors, and at the Board’s absolute discretion. There is no assurance of the timing, quantity or price of any Share Purchase, or whether or not the Company will make any Share Purchase at all. Shareholders and potential investors should therefore exercise caution when dealing in the Shares.

By order of the Board
Nanjing Leads Biolabs Co., Ltd.
南京维立志博生物科技股份有限公司
Dr. KANG XIAOQIANG
*Chairman, Executive Director and
Chief Executive Officer*

Nanjing, PRC, May 20, 2026

As at the date of this announcement, the board of directors of the Company comprises: (i) Dr. Kang Xiaoqiang (Chairman of the Board), Dr. Lai Shoupeng and Mr. Zuo Honggang as executive Directors; (ii) Mr. Zhang Yincheng, Dr. Chen Renhai and Dr. Wu Fenglan as non-executive Directors; and (iii) Dr. Zhang Hongbing, Mr. Du Yilong and Ms. Du Jiliu as independent non-executive Directors.